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Abstract  
 
Background: HIV-exposed, uninfected (HIV-EU) children represent a large proportion of children 
in southern Africa. The reasons for their poorer growth and higher morbidity and mortality than 
their HIV-unexposed peers are unclear.  
Objective: We compared anthropometry of 125 HIV-EU and 382 HIV-unexposed young 
Zambian children participating in a trial of micronutrient-fortified complementary/replacement 
food. 
Design: The randomised controlled trial provided children from age 6 to 18 months with a 
porridge flour containing either a basal or a rich level of micronutrients. Weight and length were 
measured 3-monthly and head and arm circumferences and triceps and subscapular skinfolds 
6-monthly. 
Results: There were no significant anthropometric differences between the two treatment 
groups. In unadjusted analyses, most anthropometric Z scores of HIV-EU children were lower 
than those of HIV-unexposed children; following adjustment for treatment arm, socioeconomic 
factors, breastfeeding and sex, head and arm circumference Z scores remained lower. 
Subscapular skinfold Z scores were lower among HIV-EU than HIV-unexposed children at 6 
months but not 18 months. 
Conclusions: Socioeconomic factors accounted for some but not all of the impaired growth of 
HIV-EU children. Micronutrient malnutrition may not be the socioeconomic factor responsible for 
the growth faltering. Factors acting earlier in life had irreversible effects. 
 
Key words: growth, children, HIV-exposed, micronutrients 
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Introduction 
 
Children born to HIV-infected mothers who themselves escape HIV-infection can be described 
as HIV-exposed, uninfected (HIV-EU). HIV transmission rates among breastfed infants where 
either mother or infant is provided with antiretroviral therapy during breastfeeding, as recently 
recommended,1 can be less than 10%.2 In the countries in Sub-Saharan Africa where antenatal 
HIV prevalence can be 20-30%,3 HIV-EU children may therefore be up to a quarter of all 
children born. Therefore, any health or development problems they experience are of enormous 
public health importance.  
 
Growth of HIV-EU children appears to be poorer and mortality greater than that of their HIV-
unexposed counterparts,4 although they do not do as badly as HIV-infected children. Growth 
faltering in childhood is a non-specific indicator of health problems and is associated with 
adverse effects in both the short5 and the long6 term. Although the causes of the poor growth 
and health of HIV-EU African children are not established, problems likely start early and are not 
limited to orphaned children. HIV-EU children are born with a slightly lower birth weight than 
unexposed children.7-8 Some studies have reported that they soon catch up in growth,7, 9 
whereas others have not.10 Differences in breastfeeding practices and diets available in later 
infancy, as well as whether or not mortality of the most malnourished children was accounted 
for, may explain different findings. Other factors which may contribute to the health problems of 
HIV-EU children, as well as to the differences among studies, are increased exposure to 
infections and exposure to antiretroviral drugs.4   
 
In the present study, we investigated whether provision of a nutritionally complete 
complementary or replacement food, compared with a food adequate in calories but of lower 
micronutrient density, from age 6 to 18 months would improve growth and permit HIV-EU 
children to catch up in growth with their HIV-unexposed peers. 
 
 
Methods 
 
Study design 
The Chilenje Infant Growth, Nutrition and Infection Study (CIGNIS) trial is registered as 
ISRCTN37460449 (www.controlled-trials.com/mrct). Children were randomised to one of two 
locally produced porridge flours at age 6 months, and were followed monthly for 12 months.  
Detailed methods and results of the primary outcome (prevalence of stunting at 18 months) 
have been published.11 
 
Study population and recruitment 
The trial was conducted in Chilenje, Lusaka, Zambia, from October 2005 to July 2009. Infants 
were eligible if they were 6 months +/- 2 weeks old, in generally good health, and their mothers 
gave written consent. Knowledge of maternal HIV status was not a requirement for joining the 
study but 90% of women knew their status from antenatal testing in the government health 
service. Since the focus of the present work was on HIV-EU children, only those infants whose 
mother’s HIV status was known and who themselves tested HIV-negative at 18 months are 
included in the present analyses. 
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Randomisation  
Randomisation was in blocks of 20; the code was held by the project Data Safety and 
Monitoring Board (DSMB). Infants were allocated to porridges by sequential numbers on 
recruitment.  
 
Study porridges 
The two flours, based on maize, beans, bambaranuts and groundnuts, were similar in bulk 
ingredients and macronutrient content but differed in micronutrient content (Supplementary 
Table 1). In pilot work, porridges were found to be acceptable12 to the local population and to 
displace other micronutrient-poor complementary or family foods but not to displace breast milk 
intake.13 Both porridges contained recommended macronutrient content.14 The richly-fortified 
porridge contained micronutrients to meet the WHO estimated needs14 for infants aged 9-11 
months with low breast milk intake, assuming an intake of 50 g flour/day. The basal porridge had 
micronutrients at levels which would have been in the maize component if a national maize 
fortification15-16 were introduced as previously planned. Micronutrient premixes for both flours 
were prepared by DSM (Isando, South Africa). Flour was mixed and processed by extrusion at 
Quality Commodities Ltd, Lusaka and stored for up to 6 months in a cool, well-ventilated room.  
 
Follow-up and anthropometry  
At recruitment, socio-demographic information was obtained by a pre-tested questionnaire. 
Women were given 4 kg of porridge flour each month and could return for more as required. At 
each monthly visit, women were asked how much porridge their child had consumed in the past 
2 days, and if those days were typical.  The mean and standard deviation (SD) reported intake 
of the porridge food provided was calculated for ‘typical’ days. Women were also asked if they 
were still breastfeeding, and, if so, approximately how many times a day they breastfed their 
child.  If no longer breastfeeding, they were asked when they stopped.     
 
Weight and length were measured every 3 months and other anthropometry every 6 months in 
the clinic. Anthropometric measurements were taken using calibrated equipment and 
standardized techniques,17 with children nude or wearing a diaper.  Weight was measured on a 
digital balance (to 10 g) and length on a length board to 1 mm (anthropometry equipment from 
Chasmor Ltd, London, UK). Head circumference and mid-upper arm circumference were 
measured using a fibre-glass insertion tape, and triceps and sub-scapular skinfolds using a 
precision Holtain skinfold caliper. Anthropometrists were trained using a repeat-measures 
protocol until they reached an acceptable level of proficiency 18. Measurement quality was 
maintained by achieving acceptable ranges for both the differences in measurements between 
the designated criterion anthropometrist (MC) and the other anthropometrists18 and for the total 
technical error of each measurement.19  
 
All anthropometric measurements were done in triplicate and the median used in analyses. 
Standard deviation, Z, scores were calculated using the World Health Organization (WHO) 
growth reference data.20 
 
HIV testing 
Serum samples from all children at 18 months were tested for antibodies to HIV. A serial testing 
algorithm was used. Samples were first tested using Determine HIV 1/ 2 (Inverness Medical, 
Japan). If negative, the result is taken to be negative. If positive, a second test, Unigold HIV 1/ 2 
(Trinity Biotech plc, Ireland), was used. If positive, the final result is positive but if negative, i.e. 
discordant, a third test SD-Bioline HIV 1/ 2 (Standard Diagnostics, Korea) was used and its 
result was taken to be the final result.  
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Statistical analyses 
The analysis for this study was restricted to children who completed at 18 months, were known 
HIV negative, and whose mothers’ antenatal HIV status was known.  All analyses of the effect of 
diet group were described in an analysis plan that was approved before the study was 
unblinded. 
 
Characteristics between maternal HIV groups at baseline were compared using Chi-squared 
tests for categorical variables and t-test for continuous variables. Since the randomisation was 
not stratified by maternal HIV status, we also compared diet groups within each maternal HIV 
group. Lastly, within each maternal HIV group, we compared baseline characteristics of those 
who were included in the present study and those who were not. 
 
To assess the effect of the fortified diet on child growth over time, data from the 6–18 month 
visits were combined, and mean anthropometric Z-scores were compared between diet groups. 
Random effects regression was used to account for the correlation of repeated measurements 
within children. Analyses were stratified by maternal HIV. Initial models contained fixed effects 
for time (visit), and a random intercept for each child. Visit was fit as a linear and a quadratic 
term, unless the likelihood ratio test for departure from linearity was not significant at p<0.05.  If 
the quadratic term was not adequate, visit was fit as a categorical factor. Secondary analyses 
were adjusted for a priori confounders selected because of their known associations with child 
growth: socioeconomic status (SES), maternal education, current breastfeeding, child sex, and 
baseline (6 month) Z-score (to control for possible growth deficits before the child was given the 
diet) as a continuous covariate.  SES was measured using an asset index, created by 
combining data on possessions and housing characteristics using principal component 
analysis.21 Within each maternal HIV group, changes in Z-scores over time (increase vs 
decrease) were evaluated by the estimate of the association with visit. 
 
To assess the effect of maternal HIV on child growth over time, mean anthropometric Z-scores 
were compared between children of HIV-negative and HIV-positive mothers, using random 
effects regression as described above. Initial models contained fixed effects for diet group and  
visit, and a random intercept for each child. Adjusted analyses included effects for diet group, 
visit, SES, maternal education, current breastfeeding, and child sex. A test for interaction 
between maternal HIV status and visit was done to assess whether the effect of maternal HIV 
varied over time. We did not adjust for baseline Z scores in this analysis, since baseline Z 
scores were on the causal pathway between our exposure of interest (maternal HIV status) and 
outcome (growth over time).   
 
To assess the effect of continued breastfeeding on growth over time, mean anthropometric Z-
scores were compared between children who were currently breastfeeding at the time of 
measurement and those who were not, using random effects regression as described above. 
Adjusted analyses included effects for diet group, time, SES, maternal education, child sex and 
baseline Z-score. 
   
Sample size 
Sample size calculations were based on the primary outcome of stunting at 18 months, 
assuming a prevalence of 40%22 among children receiving the basal porridge.  With a 15% loss 
to follow up, 400 children per group would provide >90% power to detect a 30% reduction in the 
prevalence of stunting, and >80% power to detect a 25% reduction (alpha=0.05). The DSMB 
reviewed the results twice (September 2007 and May 2008) and, after noting the prevalence of 
stunting was lower than anticipated, and that an increase in sample size was financially and 
logistically impossible, recommended stopping recruitment in mid-July 2008. 
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Ethics 
The study was approved by the ethics committees of the University of Zambia and the London 
School of Hygiene and Tropical Medicine. Mothers gave written informed consent. Project staff 
referred participants who were ill to local medical services and followed up treatments within 
these services.  
 
 
Results 
 
A total of 743 infants were recruited and randomised but the present analysis is restricted to the 
507 children whose mothers’ antenatal HIV status was known and who were themselves HIV-
uninfected (Figure 1). In this sub-group of children, as in the trial cohort overall,11 treatment 
groups were similar at baseline except there was a slight excess of girls in the richly-fortified diet 
group (Table 1).  In addition, among HIV-EU children, those in the richly-fortified group had 
slightly lower mean weight at 6 months and lower maternal education than those in the basal 
arm.  HIV-positive mothers were older and of lower education and SES than HIV-negative 
mothers, and all anthropometric indices at 6 months were significantly lower in HIV-EU children.  
Most strikingly, whereas virtually all HIV-uninfected women were still breastfeeding, a large 
proportion of HIV-infected women either never initiated breastfeeding or else had stopped 
before 6 months. 
 
Mothers who were included in the present study were older and more likely to be married than 
those who were not included (p<0.05), and HIV-negative mothers who were included had higher 
education than those not included. There were no differences in any of the baseline 
anthropometric indices or other characteristics of children who were included and those who 
were not. 
 
Neither the number of visits attended nor porridge consumption differed between treatment 
groups (data not shown). The median daily amount of porridge consumed increased with age 
from ~275 ml/d (~19 g flour/d) at 7 months to ~400 ml/d (~28 g flour/d) from 11 to 18 months. 
These amounts were only about half the estimated consumption used as the basis for the 
micronutrient concentrations in the richly-fortified diet. Consumption of the study diet was 
significantly greater among children of HIV-infected women, women who were not 
breastfeeding, and those with lower socioeconomic status. At 7 months, median daily porridge 
consumption among children who were breastfeeding was 250 ml/d, versus 400 ml/d among 
children who were not breastfeeding.  From 11–18 months, median daily porridge consumption 
was 400 ml/d among children who were breastfeeding, and 450 ml/d among those who were not 
breastfeeding. 
 
Between ages 6 to 18 months, there were significant decreases in length, weight, head and arm 
circumference Z scores and increases in triceps and subscapular skinfold Z scores over time, 
among both HIV-EU and HIV-unexposed children (Figure 2). In the unadjusted analyses, diet 
treatment had no significant effect on the mean Z scores of HIV-EU or HIV-unexposed children 
(Table 2).  However, after adjusting for a priori confounders, there was some evidence among 
children of HIV-negative mothers that mean head circumference-for age (adjusted mean 
difference 0.06 (95% CI -0.003, 0.11), P=0.06) and weight-for-age (adjusted mean difference 
0.08 (95% CI -0.01, 0.17), P=0.10) Z-scores were higher in the micronutrient-fortified arm.  
 
For all anthropometric variables, in the unadjusted analysis mean Z scores of HIV-EU children 
were significantly lower than those of HIV-unexposed children (Table 2).  After adjustment for 
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treatment arm, socioeconomic status, maternal education, current breastfeeding and child sex, 
mean head and arm circumference Z scores remained significantly lower in the HIV-EU 
compared with the HIV-unexposed children.  For subscapular skinfold Z scores, there was a 
significant interaction (P=0.003) between maternal HIV status and visit month, indicating that 
the effect of maternal HIV status on growth changed over time.  At the 6 and 12 month visits, 
mean subscapular skinfold Z scores were significantly lower among HIV-EU children (mean 
difference at 6m = –0.45 (95%CI –0.67 to –0.23); at 12 m = –0.27 (95%CI –0.50 to –0.05)), but 
at 18 months, there was no significant difference between maternal HIV groups in mean 
subscapular skinfold Z scores (mean difference –0.15 (95%CI –0.37 to 0.07); Figure 2). 
 
Among both HIV-EU and HIV-unexposed children, there was evidence that the effect of 
breastfeeding on length, weight, and subscapular skinfold Z scores changed over time, with 
children who were still breastfeeding at later visits having lower mean Z scores than those who 
were no longer breastfeeding (Table 3). There was no evidence of an association with 
breastfeeding and head or arm circumference Z scores, or triceps skinfold, in children of either 
maternal HIV group.  
 
 
Discussion 
 
The CIGNIS study aimed to improve health and growth of young Zambian children by providing 
high quality complementary or replacement foods from 6 to 18 months of age, a period with a 
high risk of growth faltering.23 Although intake of the diets was only half of the expected when 
we planned fortificant levels, we have previously shown that the richly-fortified diet improved 
hemoglobin and iron status of all children and reduced stunting at 18 months among non-
breastfed children of HIV-infected mothers.11 In the present work the richly-fortified diet slightly 
increased weight and head circumference of the HIV-unexposed children but did not benefit 
growth of the HIV-EU children. For ethical reasons we provided food and medical care to all 
children and thus decreased the chance of detecting benefits from the richly-fortified compared 
with the basal diet. The overall stunting rate at 18 months of 20% was only half the 40% on 
which we based sample size calculations and lower than the 36% stunting we measured among 
Chilenje clinic children aged 18 months who were not part of the CIGNIS study because they 
reached 6 months before recruitment began.11 Other anthropometric Z scores of these non-
study children from the community were similarly slightly lower than among study children (data 
not shown).  
 
Provision of nutritional complementary foods from 6 months of age was unable to reverse the 
growth deficits seen among the HIV-EU children compared with HIV-unexposed children. There 
has been relatively little research into growth of HIV-EU African children. Early research 
suggested the growth faltering compared to HIV-unexposed children was transient but our 
previous10 and current studies in Lusaka suggest some chronic and persistent growth 
impairments. There are many differences between the cohorts studied in the 1990s and the 
CIGNIS cohort. First, since our study was designed to investigate growth of HIV-EU children, we 
have more detailed anthropometric data than do previous studies. Second, the mothers and 
infants in our present and previous cohorts had access to perinatal nevirapine which prevents 
HIV infection among many high risk infants who are now part of the HIV-EU group. Third, in our 
study breastfeeding was not universal and was of limited duration. Fourth, in our study Z scores 
were calculated based on the WHO 2006 reference which crosses over the old NCHS/WHO 
growth reference within the age group we studied and thus complicates comparisons between 
studies. Our cohort represents HIV-affected women and infants in much of current urban Africa 
but the situation may soon change again as the new WHO HIV and infant feeding 
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recommendations1 are rolled out. These recommend up to a year breastfeeding while women or 
infants are given antiretroviral drugs and should thus both increase breastfeeding rates and, by 
decreasing HIV transmission, increase the proportion of HIV-EU children. 
 
Differences in anthropometric Z scores between HIV-EU and HIV-unexposed children were all 
statistically significant before adjustment for confounders and were about 0.3 to 0.4, depending 
on the index, which are large enough to be a concern on a population basis. Furthermore, at 
enrolment, all anthropometric measures were significantly lower among HIV-EU children. Since 
we recruited only relatively healthy children aged 6 months, it is possible that the children most 
at risk of growth faltering, because of being born low birth weight, having a mother with 
advanced HIV, or succumbing to illness because of early lack of breastfeeding, had died before 
becoming eligible for our study. Therefore, we believe our results may underestimate the growth 
deficit of HIV-EU children.  
 
Adjustment for breastfeeding and socioeconomic factors, that is, maternal education and tertile 
of asset index score, decreased, but did not eliminate, the differences in Z scores seen between 
HIV-EU and HIV-unexposed children. For all anthropometric measures, there was still some 
evidence of a negative effect after adjustment, although not always statistically significant.  
Furthermore, since few HIV-EU children were still breastfeeding at 6 months, the adjustment for 
breastfeeding was not very efficient, so we may have underestimated the effect of maternal HIV. 
The lower socioeconomic status of the HIV-infected women may contribute to the poorer growth 
of their children. Within high HIV prevalence African countries, socioeconomic factors have less 
association with HIV acquisition than in Western countries.24 Lower socioeconomic status, on 
the other hand, may result from HIV infection of working-age adults since it can impair their 
ability to earn money. Programmes such as food aid for HIV-exposed families may mitigate 
some of the effects of poverty. However, the present study indicates that provision of food to 
HIV-EU children from 6 months is too late to reverse the growth faltering which was present 
since birth. It remains to be seen whether provision of food aid to pregnant HIV-infected women 
could increase birth weight of their infants and reduce subsequent growth faltering. Provision of 
multivitamins to HIV-infected Tanzanian women increased weight at birth25 and at 24 months26 
of HIV-EU children.  
 
The decrease between 6 and 18 months in length-for-age Z scores of even the HIV-unexposed 
children in this fairly middle income African population given free food suggests that nutrition 
after 6 months is not their main cause of growth faltering but other factors, such as exposure to 
infections, may be more important. Compared with HIV-unexposed children, HIV-EU children 
may be exposed to more infections because of their sick parents and may also be less resistant 
to infections, as indicated by their elevated mortality.4 We have shown higher rates of hospital 
referral among HIV-exposed versus unexposed children in the CIGNIS study.11 
 
Subscapular skinfolds of the HIV-EU children approached those of the HIV-unexposed children 
between 6 and 18 months. It is debatable whether this growth in central fat is beneficial since 
early rapid increases in body fat have been associated amongst non-HIV-exposed children with 
later risk of chronic disease.27-28 Deposition of this fat centrally, rather than at peripheral sites, 
may be a response to stresses, such as exposure to maternal HIV in utero or during lactation. 
The consequences of deposition of increased central fat in this population, especially when 
exposed to the nutrition transition currently experienced by urban Zambia based on its rapidly 
increasing rates of overweight and obesity,29 remain unknown. It will be important to follow up 
these children to determine whether they develop risk factors for chronic disease and, if so, 
whether these can be ameliorated through lifestyle interventions. 
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The effect of breastfeeding on anthropometry appeared to change with time, significantly for 
weight, length and subscapular skinfolds of both HIV-EU children and HIV-unexposed children. 
The trend towards lower Z scores among children breastfed after 12 months may represent 
reverse causality, that is, mothers continued to breastfeed children who were growing poorly. 
The 12 month time point suggested by WHO1 as time to stop breastfeeding HIV-EU children 
was largely speculative but our results suggest it is reasonable in a population such as ours with 
access to clean water and adequate food. 
 
A limitation of our study is the restriction to children who completed at 18 months, since PCR 
was not routinely available to test children for HIV at younger ages.  However, there were no 
differences in most maternal characteristics, or in any anthropometric indices at 6 months, 
between children who were included and those excluded, so we believe our results to be 
generalisable. 
 
Provision of nutritional complementary food was unable to reverse growth faltering among HIV-
EU children. Growth faltering is known to result from both poor nutrition and increased infection 
and our results suggest that nutrition and infection in the mother as well as the child need to be 
considered in health programs. In general, it is better to prevent growth faltering than to try to 
remedy it. Micronutrient supplementation of HIV-infected women should be explored further, 
based on its beneficial effects in Tanzania.25-26 Many African countries are now instituting 
programmes which provide antiretroviral therapy to women in late pregnancy, not just to 
mothers and their infants at delivery. With the new WHO guidelines, these antiretrovirals may 
soon be extended through lactation. It will be important to monitor whether these programmes 
reduce the growth and health problems of HIV-EU children. 
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Table 1. Baseline characteristics of 507 HIV-negative children completing the trial and of known maternal HIV status 
  
 HIV-unexposed children HIV-exposed, uninfected children 
Diet treatment group1 
Basal 
Richly-
fortified 
All HIV-
unexposed 
Basal 
Richly-
fortified 
All HIV-
exposed 
uninfected2 
N 190 192 382 66 59 125 
Mother’s age (years) 25.8 (SD 5.8) 26.1 (SD 5.8) 25.9 (SD=5.8) 28.3 (SD 5.3) 29.4 (SD 5.4) 28.8 (SD=5.4) 
Maternal body mass 
index (kg/m2) 
   
   
<18.5 
18.5 – 25 
25-30 
>30 
13 (7%) 
115 (61%) 
42 (22%) 
20 (11%) 
17 (9%) 
105 (55%) 
47 (24%) 
23 (12%) 
30 (8%) 
220 (58%) 
89 (23%) 
43 (11%) 
6 (9%) 
34 (52%) 
21 (32%) 
5 (8%) 
5 (8%) 
36 (61%) 
12 (20%) 
6 (10%) 
11 (9%) 
70 (56%) 
33 (26%) 
11 (9%) 
Mother’s education                  
primary or less 
secondary 
college/university 
58 (31%) 
77 (41%) 
55 (29%) 
48 (25%) 
76 (40%) 
68 (35%) 
106 (28%) 
153 (40%) 
123 (32%) 
20 (30%) 
31 (47%) 
15 (23%) 
32 (54%) 
16 (27%) 
11 (19%) 
52 (42%) 
47 (38%) 
26 (21%) 
Mother’s occupation             
housewife 
salaried employee 
self-employed 
other 
104 (55%) 
39 (21%) 
18 (9%) 
29 (15%) 
93 (48%) 
45 (23%) 
16 (8%) 
38 (20%) 
197 (52%) 
84 (22%) 
34 (9%) 
67 (18%) 
41 (62%) 
9 (14%) 
10 (15%) 
6 (9%) 
35 (59%) 
14 (23%) 
4 (7%) 
6 (10%) 
76 (61%) 
23 (18%) 
14 (11%) 
12 (10%) 
Marital status                     
married 
single 
divorced, separated, 
widowed   
144 (76%) 
37 (19%) 
9 (5%) 
153 (80%) 
35 (18%) 
4 (2%) 
297 (78%) 
72 (19%) 
13 (3%) 
52 (79%) 
10 (15%) 
4 (6%) 
46 (78%) 
7 (12%) 
6 (10%) 
98 (78%) 
17 (14%) 
10 (8%) 
Tertiles of 
socioeconomic status 
   
   
low 
middle 
high 
55 (29%) 
79 (42%) 
56 (29%) 
59 (31%) 
74 (39%) 
59 (31%) 
114 (30%) 
153 (40%) 
115 (30%) 
25 (38%) 
25 (38%) 
16 (24%) 
28 (47%) 
17 (29%) 
14 (24%) 
53 (42%) 
42 (34%) 
30 (24%) 
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1
Significant differences between diet groups among children of HIV-positive mothers: maternal education (p=0.02) and weight at 6m (p=0.09).   
2
Significant differences between maternal HIV groups: maternal age (p<0.001), education (p=0.006), occupation (p=0.04), SES (p=0.03), marital status 
(p=0.05), all anthropometric indicators at 6m (p=0.06 for triceps; p≤0.003 for all others), breastfeeding duration (p<0.001). 
  
Infant characteristics       
Sex (#, % F) 
 
86 (45%) 
 
102 (53%) 
 
188 (49%) 
 
34 (52%) 
 
36 (61%) 
 
70 (56%) 
 
Birth weight (kg) 
 
3.06 (SD 0.54) 
 
3.08 (SD 0.47) 
 
3.07 (SD 0.50) 
 
3.04 (SD 0.46) 
 
2.93 (SD 0.52) 
 
2.99 (SD 0.49) 
 
Anthropometry at 6 months      
Weight (kg) 
 
7.36 (SD 0.99) 
 
7.40 (SD 1.12) 
 
7.38 (SD 1.06) 
 
7.20 (SD 1.04) 
 
6.88 (SD 1.08) 
 
7.05 (SD 1.07) 
 
Length (cm) 65.1 (SD 2.3) 65.0 (SD 2.8) 65.1 (SD 2.5) 64.6 (SD 2.4) 63.9 (SD 2.6) 64.3 (SD 2.5) 
 
Head circumference 
(cm) 
43.7 (SD 1.4) 43.7 (SD 1.4) 43.7 (SD 1.4) 43.3 (SD 1.3) 43.1 (SD 1.5) 43.2 (SD 1.4) 
 
Arm circumference (cm) 14.5 (SD 1.2) 14.6 (SD 1.3) 14.6 (SD 1.3) 14.1 (SD 1.3) 13.8 (SD 1.4) 14.0 (SD 1.3) 
 
Triceps skinfold (mm) 9.1 (SD 1.7) 9.3 (SD 1.8) 9.2 (SD 1.8) 8.8 (SD 2.0) 8.9 (SD 1.7) 8.8 (SD 1.8) 
 
Subscapular skinfold 
(mm) 
8.1 (SD 1.6) 8.2 (SD 1.7) 8.2 (SD 1.7) 7.7 (SD 2.0) 7.5 (SD 1.7) 7.6 (SD 1.9) 
 
Hemoglobin at 6 months 
(g/L) 
107 (SD 12) 108 (SD 14) 108 (SD 13) 109 (SD 11) 106 (SD 12) 108 (SD 12) 
Breastfeeding duration:       
never 
<6 months 
breastfeeding at 
recruitment 
1 (0.5%) 
7 (4%) 
182 (96%) 
0 (0%) 
4 (2%) 
320 (98%) 
1 (0.3%) 
11 (3%) 
370 (97%) 
18 (27%) 
23 (35%) 
25 (38%) 
13 (22%) 
19 (32%) 
27 (46%) 
31 (25%) 
42 (34%) 
52 (42%) 
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Table 2. Effects of treatment arm and maternal HIV status on growth and body composition Z scores during follow-up, in 
HIV-negative children completing at 18 months HIV-negative children completing at 18 months 
 HIV negative mother (N=382) HIV positive mother (N=125) Unadjusted 
mean 
difference 
between 
maternal 
HIV groups 
(95% CI)
3
 
Adjusted 
mean 
difference 
between 
maternal HIV 
groups 
(95% CI)
4
 
 
Overall 
mean
1
 (SD) 
Unadjusted 
mean 
difference 
between 
diets  
(95% CI)
 
 
Adjusted 
mean 
difference 
between 
diets  
(95% CI)
2
 
Overall 
mean
1
 (SD) 
Unadjusted 
mean 
difference 
between 
diets  
(95% CI) 
Adjusted 
mean 
difference 
between 
diets  
(95% CI)
2
 
Length for age Z score        
Basal diet –0.87 (1.02) 
0.08  
(-0.13, 0.29) 
0.04 
 (-0.05, 0.12) 
–1.06 (1.17) 
–0.09  
(-0.48, 0.29) 
0.09  
(-0.06, 0.24) 
–0.28  
(-0.49, –0.06) 
–0.15  
(-0.35, 0.06) 
Fortified diet –0.80 (1.18) P=0.46 P=0.39 –1.18 (1.14) P=0.63 P=0.25 P=0.01 P=0.16 
Weight for age Z score        
Basal diet –0.47 (1.13) 
0.16  
(-0.07, 0.39) 
0.08 
 (-0.01, 0.17) 
–0.58 (1.27) 
–0.20  
(-0.63, 0.23) 
0.10  
(-0.05, 0.25) 
–0.30  
(–0.53, –
0.06) 
–0.14  
(–0.37, 0.09) 
Fortified diet –0.31 (1.25) P=0.17 P=0.10 –0.80 (1.29) P=0.37 P=0.18 P=0.01 P=0.22 
Head circumference for age Z score       
Basal diet 0.61 (1.02) 
0.12 
 (-0.07, 0.31) 
0.06 
 (-0.003, 
0.11) 
0.38 (1.02) 
–0.006  
(-0.37, 0.36) 
0.01  
(-0.11, 0.14) 
–0.30  
(-0.49, –0.10) 
–0.21  
(-0.40, –0.01) 
Fortified diet 0.73 (0.95) P=0.21 P=0.06 0.37 (1.16) P=0.97 P=0.85 P=0.003 P=0.04 
Arm circumference for age Z score       
Basal diet 0.28 (1.03) 
0.15 
 (-0.04, 0.34) 
0.06 
 (-0.03, 0.14) 
0.01 (1.25) 
–0.19  
(-0.60, 0.22) 
0.06  
(-0.11, 0.23) 
–0.44  
(-0.64, –0.23) 
–0.24  
(-0.45, –0.04) 
Fortified diet 0.43 (1.10) P=0.13 P=0.21 –0.19 (1.27) P=0.36 P=0.46 P<0.001 P=0.02 
Triceps skinfold for age Z score       
Basal diet 0.12 (0.96) 
0.09 
 (-0.08, 0.25) 
0.04 
 (-0.05, 0.13) 
–0.06 (1.15) 
0.08  
(-0.25, 0.41) 
0.04  
(-0.12, 0.20) 
–0.19  
(-0.36, –0.02) 
–0.05  
(–0.23, 0.13) 
Fortified diet 0.21 (1.00) P=0.30 P=0.40 0.01 (0.97) P=0.64 P=0.65 P=0.03 P=0.59 
Subscapular skinfold for age Z score       
Basal diet 0.59 (1.02) 
0.05 
 (-0.13, 0.23) 
0.02 
 (-0.08, 0.12) 
0.36 (1.32) 
–0.08  
(-0.46, 0.30) 
0.02  
(-0.16, 0.19) 
* * 
Fortified diet 0.64 (1.09) P=0.61 P=0.69 0.28 (1.11) P=0.67 P=0.86 P=0.009
5
 P=0.003
5
 
 
15 
 
1 Based on data from 6–18 month visits combined and using random effects regression to account for the correlation of repeated 
measurements within children. For HIV-negative mothers, from 190 children on basal diet and 192 on fortified diet; for HIV-positive 
mothers, from 66 children on basal diet and 59 on fortified diet.   
2Adjusted for visit, SES, maternal education, current breastfeeding, sex and Z-score at 6 months, from repeated-measures random-
effects regression.   
3Adjusted for diet treatment group and visit month, from repeated-measures random-effects regression.   
4Adjusted for diet treatment group, visit, SES, maternal education, current breastfeeding and sex, from repeated-measures random-
effects regression  
5P-value for interaction; unadjusted difference at 6m is -0.45 (95%CI -0.67 to -0.22); at 12m is -0.27 (95%CI -0.49 to -0.05); and at 
18m is -0.15 (95%CI -0.37 to 0.07).  Adjusted difference at 6m is  -0.36 (95% CI -0.06 to -0.13); at 12m is -0.18 (95% CI -0.42 to 
0.06); and at 18m is -0.08 (95% CI -0.30 to 0.15).   
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Table 3. Effects of concurrent breastfeeding on growth and body composition Z scores during follow-up, in HIV-negative 
children completing at 18 months 
 
HIV negative mother HIV positive mother 
Not breastfeeding Breastfeeding Difference by 
breastfeeding 
(95% CI)1 
Not breastfeeding Breastfeeding Difference by 
breastfeeding 
(95% CI) 1 N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
Length for age Z score    P-int=0.042     P-int=0.052 
6 months 12 -0.78 (0.98) 369 -0.77 (1.08) 0.21 (-0.04, 0.46)  73 -1.09 (1.06) 52 -0.93 (1.04) 0.24 (0.08, 0.40)  
9 months 17 -0.55 (1.00) 354 -0.73 (1.09) 0.15 (-0.06, 0.37)  92 -1.01 (1.17) 28 -0.87  (1.10) 0.03 (-0.17, 0.23)  
12 months 38 -0.46 (1.08) 330 -0.82 (1.12) -0.03 (-0.18, 0.12)  102 -1.04 (1.13) 22 -1.06 (1.05) 0.22 (0.003, 0.44)  
15 months 97 -0.77 (1.08) 265 -0.93 (1.10) -0.04 (-0.14, 0.06)  104 -1.15 (1.25) 15 -1.35 (1.08) -0.07 (-0.32, 0.19)  
18 months 209 -0.87 (1.14) 171 -1.20 (1.09) -0.04 (-0.13, 0.05)  112 -1.33 (1.22) 13 -1.47 (1.13) -0.05 (-0.31, 0.22)  
Weight for age Z score    P-int<0.0012     P-int=0.0032 
6 months 12 -0.37 (1.40) 369 -0.37 (1.19) 0.65 (0.38, 0.93)  73 -0.86 (1.23) 52 -0.49 (1.33) 0.20 (0.05, 0.35)  
9 months 17 0.19 (1.49) 354 -0.37 (1.16) 0.11 (-0.12, 0.34)  92 -0.71 (1.27) 28 -0.26 (1.23) 0.10 (-0.09, 0.29)  
12 months 38 0.06 (1.47) 331 -0.39 (1.17) 0.01 (-0.15, 0.17)  102 -0.60 (1.30) 22 -0.63 (1.39) -0.06 (-0.27, 0.14)  
15 months 97 -0.19 (1.30) 266 -0.48 (1.14) -0.10 (-0.21, 0.01)  106 -0.73 (1.30) 15 -0.78 (1.39) -0.10 (-0.34, 0.14)  
18 months 210 -0.33 (1.18) 171 -0.68 (1.20) -0.07 (-0.16, 0.03)  112 -0.77 (1.24) 13 -0.84 (1.47) -0.16 (-0.42, 0.09)  
Head circumference for age Z score       
6 months 12 0.72 (0.99) 369 0.74 (1.01) 
-0.007 (-0.07, 0.06), 
P=0.84 
73 0.19 (1.08) 52 0.71 (0.88) 
0.04 (-0.08, 0.17), 
P=0.50 
12 months 38 0.70 (0.99) 331 0.66 (0.99) 102 0.34 (1.15) 22 0.51 (1.06) 
18 months 209 0.70 (0.92) 170 0.51 (0.99) 111 0.36 (1.12) 13 0.31 (0.95) 
Arm circumference for age Z score       
6 months 12 0.11 (1.57) 369 0.45 (1.08) 
-0.005 (-0.11, 0.10), 
P=0.93 
73 -0.22 (1.17) 52 0.20 (1.24) 
0.08 (-0.10, 0.27), 
P=0.39 
12 months 38 0.53 (1.27) 331 0.44 (1.02) 101 -0.06 (1.23) 22 0.31 (1.45) 
18 months 208 0.25 (1.07) 171 0.10 (1.00) 112 -0.23 (1.26) 13 -0.04 (1.59) 
Triceps skinfold for age Z score       
6 months 12 -0.29 (1.47) 369 -0.06 (1.03) 
0.09 (–0.03, 0.20), 
P=0.16 
73 -0.43 (1.12) 52 -0.10 (1.08) 
0.06 (-0.12, 0.24), 
P=0.49 
12 months 38 0.30 (1.10) 331 0.33 (0.90) 102 0.10 (1.04) 22 0.37 (1.36) 
18 months 209 0.23 (0.91) 171 0.25 (0.94) 112 0.06 (0.92) 13 0.08 (1.25) 
Subscapular skinfold for age Z score   P-int=0.042     P-int=0.0092 
6 months 12 0.17 (1.38) 369 0.59 (1.15) 0.32 (-0.09, 0.73)  73 -0.17 (1.39) 52 0.54 (1.17) 0.22 (-0.04, 0.49)  
12 months 38 0.67 (1.20) 331 0.69 (1.02) -0.04 (-0.28, 0.20)  102 0.36 (1.09) 22 0.69 (1.40) -0.21 (-0.56, 0.13)  
18 months 209 0.63 (0.94) 171 0.52 (1.02) -0.15 (-0.30, -0.01)  112 0.40 (1.11) 13 0.72 (1.41) -0.36 (-0.78, 0.07)  
1Adjusted for diet group, visit, socioeconomic status, maternal education, sex and baseline Z score, from repeated-measures 
random-effects regression 
2Significant interaction between current breastfeeding & time (visit) – i.e. the effect of breastfeeding on growth varies over time
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Supplementary Table 1. Composition of the trial porridge flours  
 
 Basal fortification 
(per kg flour)1 
Rich fortification 
(per kg flour)2 
maize 650 g 615 g 
groundnuts 150 g 150 g 
bambaranuts 50 g 50 g 
beans (white and yellow) 150 g 150 g 
energy 4200 kcal 4140 kcal 
protein 15% 15% 
fat 12% 12% 
vitamin A 0.65 RE 6.5 RE 
vitamin C  2.0 g 
vitamin D  0.1 mg 
thiamin (mononitrate) 1.3 mg 9 mg 
riboflavin 1.6 mg 11.2 mg 
niacin (niacinamide) 13 mg 140 mg 
pyridoxine (HCl) 1.6 mg 8.6 mg 
folate 0.65 mg 2.21 mg 
B12 3.25 g 9.75 g 
pantothenic acid  40.3 mg 
magnesium (oxide)  943 mg 
iron (ferrous fumarate)3 6.5 mg 250 mg 
zinc (oxide)3  9.75 mg 200 mg 
copper (gluconate)  3.2 mg 
manganese (sulfate monohydrate)  12.0 mg 
selenium (sodium selenite)  0.2 mg 
calcium (CaH(PO4)*2H2O)
3  6.8 g 
phosphorus (CaH(PO4)*2H2O)  5.3 g 
 
1Based on estimated amounts of micronutrients which would be available from 50 g porridge 
flour/day made with maize fortified at levels planned nationally for Zambia. Overages (usually 
10%) added to allow for losses during processing. 
2Based on total estimated micronutrient needs of infants aged 9-11 months minus amounts 
expected from low breast milk intakes 14 and assuming intake of 50g porridge flour/day. 
Exceptions to the micronutrient levels are that vitamin C was increased to compensate for low 
iron bioavailability and zinc was based on Recommended Daily Allowance set by the 
International Zinc Consultative Group. 30 Overages (usually 10%) added to allow for losses 
during processing. 
3 Phytate was analysed in two batches of each flour and averaged 5.8 g/kg. This translated into 
phytate:zinc molar ratios of ~19 in the basal flour and ~3.3 in the richly fortified flour and 
phytate:iron molar ratios of 5.6 and 1.7 in the two flours, respectively. 
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Figure legends 
 
Figure 1. Flow diagram of participants through the study 
 
Sixty-eight children were inadequately randomised because one porridge supply ran out; these 
children were excluded from analyses. 
 
Figure 2. Anthropometric Z scores of HIV-exposed, uninfected and HIV-unexposed children  
 
Numbers of children were 190 HIV-unexposed in the basal diet group, 192 HIV-unexposed in 
the richly-fortified diet group, 66 HIV-EU in the basal diet group, and 59 HIV-EU in the richly-
fortified group. 
 
